Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Novo Nordisk A/SNYSE: NVO

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows, but more slowly than its trailing trend

Q2 FY2026 revenue of DKK 78.49B rose 2.1% year over year, behind the +5.6% change in trailing-twelve-month revenue. Sequentially, it fell 18.9% from the prior quarter. Over 3 fiscal years it compounded at +20.4% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 16 analysts of DKK 310.44B (+0.4%) for the fiscal year ending Dec 2026, a slowdown from the +6.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
DKK 78.49B-18.9% QoQ
Last fiscal yearDec 2025
DKK 309.06B+6.4% YoY
LTMJun 2026
DKK 329.43B+5.6% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.1%-1.2%-3.3 pp
1 year+6.4%+0.4%-6.0 pp
3-year CAGR+20.4%+2.7%-17.7 pp
5-year CAGR+3.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

DKK · from the income statement

Latest · FY2025
309.06B DKK
Year-over-year change
+6.4%
4-year CAGR
+21.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +5.6% is the 7th highest of 10, against a peer median of +7.8%.
  • Over three fiscal years its annual growth of +20.4% compares with a peer median of +4.8%.
NVO Competitors
Revenue for NVO and competitors
Company Period LTM YoY 3-year CAGR
NVONovo Nordisk A/SLTM Jun 2026DKK 329.43B DKK+5.6%+20.4%
JNJJohnson & JohnsonLTM Sep 2026$99.34B USD+7.8%+5.6%
LLYEli Lilly and CompanyLTM Jun 2026$79.67B USD+49.6%+31.7%
MRKMerck & Co., Inc.LTM Jun 2026$66.4B USD+4.2%+3.1%
ABBVAbbVie Inc.LTM Sep 2026$66.01B USD+10.7%+1.8%
PFEPfizer Inc.LTM Jun 2026$63.7B USD-0.2%-14.8%
AZNAstraZeneca PLCLTM Sep 2026$62.17B USD+7.0%+9.8%
SNYSanofiLTM Jun 2026€48.92B EUR+13.4%+4.8%
AMGNAmgen Inc.LTM Jun 2026$38.13B USD+9.2%+11.8%
GSKGSK plcLTM Jun 2026£33.2B GBP+5.0%+3.7%
Peer median (excluding NVO) —+7.8%+4.8%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue140.8B176.95B232.26B290.4B309.06B
Cost of Revenue23.66B28.45B35.77B44.52B58.79B
Gross Profit117.14B148.51B196.5B245.88B250.28B
Gross Margin83.2%83.9%84.6%84.7%81.0%
Research & Development17.77B24.05B32.44B48.06B52.04B
Selling, General & Admin41.06B50.68B61.6B67.38B70.28B
Operating Expenses58.5B73.7B93.92B117.54B122.62B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
EBITDA65.39B76.8B114.63B147.94B156.73B
EBITDA Margin46.4%43.4%49.4%50.9%50.7%
Operating Income58.64B74.81B102.57B128.34B127.66B
Operating Margin41.7%42.3%44.2%44.2%41.3%
Interest Income231M239M1.07B1.84B1.27B
Interest Expense289M378M542M1.64B4.21B
Other Income / Expenses436M(5.75B)2.1B(1.15B)2.88B
Income Before Tax59.08B69.06B104.67B127.19B130.54B
Pre-Tax Margin42.0%39.0%45.1%43.8%42.2%
Income Tax Expense11.32B13.54B20.99B26.2B28.11B
Net Income47.76B55.53B83.68B100.99B102.43B
Net Margin33.9%31.4%36.0%34.8%33.1%
EPS (Basic)10.4012.2618.6722.6723.06
EPS (Diluted)10.3712.2218.6222.6323.03
Weighted Avg Shares4.59B4.53B4.48B4.45B4.45B
Weighted Avg Shares (Diluted)4.61B4.54B4.49B4.46B4.45B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.